Docetaxel Induced Sclerosing Cholangitis

Horsley‐Silva, Jennifer L.; Dow, Elizabeth N.; Menias, Christine O.; Smith, Maxwell L.; Carballido, Estrella M.; Lindor, Keith D.; Vargas, Hugo E.

doi:10.1007/s10620-015-3914-3

Cited by 21 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatic intra-arterial infusion of chemotherapy drugs was reported to lead to sclerosing cholangitis more than 30 years ago (47, 48). Since then several case reports of idiosyncratic DILI causing secondary sclerosing cholangitis have been published (41, 43, 49, 50). …”

Section: Specific Chronic Injuriesmentioning

confidence: 99%

Long-Term Outcomes After Drug-Induced Liver Injury

Hayashi

Bjõrnsson

2018

Curr Hepatology Rep

View full text Add to dashboard Cite

Purpose of the review: This review serves to update the reader on emerging data regarding a spectrum of drug-induced liver injury (DILI) outcomes that lie between complete resolution and acute liver failure. Such outcomes can range from mild chronic injury to late liver failure and mortality. Recent findings: Several large registries are maturing with large numbers of DILI cases thus shedding light on outcomes including chronic injury and late fatality. We cover definitions commonly used to describe resolution versus chronic injury and mortality due to DILI. We look at rates of occurrence for these different outcomes in major registries. Three specific types of chronic DILI that are illustrative but also easily missed by clinicians are also described. Summary: A small but important proportion of DILI cases do not resolve, going on to develop chronic injury and even liver failure. Defining and recognizing these cases is a challenge because DILI is rare, and chronic injury rarer still. Large registries are beginning to define these previously overlooked long term outcomes.

show abstract

Section: Specific Chronic Injuriesmentioning

confidence: 99%

Long-Term Outcomes After Drug-Induced Liver Injury

Hayashi

Bjõrnsson

2018

Curr Hepatology Rep

View full text Add to dashboard Cite

show abstract

“…(55)(56)(57) Secondary sclerosing cholangitis associated with the use of docetaxel was recently reported. (58) A recent study of cholangiographies among patients with DILI suggested that up to 10% of DILI cases may have sclerosing cholangitis-like changes on magnetic resonance cholangio pancreatography. (59) Recently presented findings from Ahmad et al (60) from the DILI network cohort identified four cases of druginduced secondary sclerosing cholangitis (7%) from a total of 56 patients with biliary imaging.…”

Section: Secondary Sclerosing Cholangitismentioning

confidence: 99%

Drug-Induced Cholestasis

Bjõrnsson

Jonasson

2013

Clinics in Liver Disease

View full text Add to dashboard Cite

“…The therapeutic effect of DTX is reported to be more potent than that of paclitaxel . As a second‐generation taxane, DTX works through binding to microtubules and inhibiting mitosis of cancerous cells . More specifically, it plays an anticancer role during metaphase and anaphase of mitotic cell division by stabilizing the microtubule arrays, inhibiting the microtubule de‐polymerization, and facilitating the polymerization of tubulin dimers and the formation of microtubules, which leads to the cessation of growth and apoptosis of cancerous cells .…”

Section: Introductionmentioning

confidence: 99%

“…Docetaxel (DTX) is as emi-synthetic derivative of paclitaxel, which gained approvala sachemotherapeutic agent from the US Food and Drug Administration in 1996 and the Indian Central Drugs Standard Control Organizationi n2 006. [1,2] The therapeutic effect of DTX is reported to be more potent than that of paclitaxel. [1] As as econd-generation taxane, DTX works through binding to microtubules and inhibiting mitosis of cancerous cells.…”

Section: Introductionmentioning

confidence: 99%

“…[1] As as econd-generation taxane, DTX works through binding to microtubules and inhibiting mitosis of cancerous cells. [2] More specifically,i tp lays an anticancer role during metaphase and anaphase of mitotic cell divisionb ys tabilizing the microtubule arrays, inhibiting the microtubule depolymerization, and facilitating the polymerization of tubulin dimers and the formation of microtubules,w hich leads to the cessation of growth anda poptosis of cancerous cells. [1,3] DTX has been widely used with success among patients with multifarious solid tumors including breast, ovarian, prostate,l ung, head/neck, small cell lung and non-small cell lung cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multifunctional Mixed Micelles for Efficient Docetaxol Delivery for Cancer Therapy

Zhang

et al. 2016

ChemPlusChem

View full text Add to dashboard Cite

The objective of this study was to build mixed micelles based on two functional co‐polymers, including the redox‐sensitive polymer–drug conjugate methoxy poly(ethylene glycol)–poly(γ‐benzyl l‐glutamate)‐disulfide‐docetaxel (PEG–PBLG‐SS‐DTX) and the actively targeting methoxy poly(ethylene glycol)–folic acid (PEG–FA), for enhanced target specificity and improved anticancer efficiency of docetaxel (DTX). The spherical PEG–PBLG‐SS‐DTX/PEG–FA mixed micelles prepared by the dialysis method revealed a narrowly distributed size at 129.7±2.1 nm with low polydispersity of 0.10±0.02. Furthermore, the critical micelle concentration of the mixed micelles was 5.08 μg mL−1, indicating excellent self‐assembly ability in water and stability against dilution in blood circulation. The in vitro release study revealed that the conjugated DTX was rapidly released in response to dl‐dithiothreitol (DTT), a reducing agent. Only 12.3 % of DTX was released from the mixed micelles after 120 h in the absence of DTT. However, the accumulative release of DTX dramatically accelerated and reached more than 40 % in 120 h after addition of DTT. The in vitro cytotoxicity, cellular uptake and cell apoptosis experiments on the mixed micelles were performed using MTT assay, fluorescence inverted microscopy and flow cytometric analysis, and 4′,6‐diamidino‐2‐phenylindole (DAPI) staining, respectively, on folate receptor (FR)‐negative A549 and FR‐positive MCF‐7 cells. The mixed micelles could be taken up efficiently by MCF‐7 cells by FR‐mediated endocytosis compared with PEG–PBLG‐SS‐DTX micelles. Furthermore, remarkable cytotoxicity and cell apoptosis were identified for the mixed micelles against MCF‐7 cells, which was consistent with the results of the cellular uptake study. On the basis of these results, the redox‐sensitive PEG–PBLG‐SS‐DTX/PEG–FA mixed micelles using FA as a targeting ligand revealed prominent antitumor efficiency and might be a latent drug carrier for cancer chemotherapy.

show abstract

Docetaxel Induced Sclerosing Cholangitis

Cited by 21 publications

References 8 publications

Long-Term Outcomes After Drug-Induced Liver Injury

Long-Term Outcomes After Drug-Induced Liver Injury

Drug-Induced Cholestasis

Multifunctional Mixed Micelles for Efficient Docetaxol Delivery for Cancer Therapy

Contact Info

Product

Resources

About